The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Abstract
Objective. —To examine more closely the association between apolipoprotein E (APOE) genotype and Alzheimer disease (AD) by age and sex in populations of various ethnic and racial denominations. Data Sources. —Forty research teams contributed data onAPOEgenotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources. Main Outcome Measures. —Odds ratios (ORs) and 95% confidence intervals (Cls) for AD, adjusted for age and study and stratified by major ethnic group (Caucasian, African American, Hispanic, and Japanese) and source, were computed forAPOEgenotypes ∈2/∈2,∈2/∈3,∈2/∈4,∈3/∈4 and ∈4/∈4 relative to the ∈3/∈3 group. The influence of age and sex on the OR for each genotype was assessed using logistic regression procedures. Results. —Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes ∈2/∈4 (OR=2.6, 95% Cl=1.6-4.0), ∈3/∈4 (OR=3.2, 95% Cl=2.8-3.8), and ∈4/∈4 (OR=14.9, 95% CI=10.8-20.6); whereas, the ORs were decreased for people with genotypes ∈2/∈2 (OR=0.6, 95% Cl=0.2-2.0) and ∈2/∈3 (OR=0.6, 95% Cl=0.5-0.8). TheAPOE∈4-AD association was weaker among African Americans and Hispanics, but there was significant heterogeneity in ORs among studies of African Americans (P<.03). TheAPOE∈4—AD association in Japanese subjects was stronger than in Caucasian subjects (∈3/∈4: OR=5.6, 95% Cl=3.9-8.0; ∈4/∈4: OR=33.1, 95% Cl=13.6-80.5). The ∈2/∈3 genotype appears equally protective across ethnic groups. We also found that among Caucasians,APOEgenotype distributions are similar in groups of patients with AD whose diagnoses were determined clinically or by autopsy. In addition, we found that theAPOE∈4 effect is evident at all ages between 40 and 90 years but diminishes after age 70 years and that the risk of AD associated with a given genotype varies with sex. Conclusions. —TheAPOE∈4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women. The association betweenAPOE∈4 and AD in African Americans requires clarification, and the attenuated effect ofAPOE∈4 in Hispanics should be investigated further.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The greatest risk factors for late-onset Alzheimer's are older age, 62,63 genetics 64,65 -especially the e4 form of the apolipoprotein E (APOE) gene -and having a family history of Alzheimer's.[66][67][68][69]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [65]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Also, previous studies of clinically and neuropathologically characterized cases and controls may have been too small to demonstrate that APOE2 homozygotes have an even lower OR than the relatively low-risk APOE2/3 group due to the paucity of APOE2 homozygotes, who comprise <1% of the general population1,4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Fourth, findings from our non-Hispanic White groups cannot yet be extended to other ethnic and racial groups4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“APOE is genetically linked to late-onset sporadic Alzheimer’s disease (LOAD), with APOE4 being a significant risk factor, APOE3 considered the “neutral” allele, and APOE2 exerting a protective role against LOAD [6, 7].”
In the citing paper
“In addition, APOE4 is linked to hypercholesterolemia and increased risk of cardiovascular disorders (CVD) [7, 41]”
In the citing paper
“Compared to ε3 homozygotes, individuals with one or two ε4 alleles harbor approximately 3 and 15 times increased risk, respectively”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“whereas carriers of the protective ε2 allele have an estimated 1.7 times decreased risk [1]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“Between 45% and 50% of AD patients carry at least one APOE4 allele compared to only 15% of age-matched healthy controls.5,11”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [11]
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4 5,6 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“Population studies have demonstrated that the ε4 allele increases the risk of developing AD by either 3-fold (1 allele) or 12-fold (2 alleles) [6]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [6]
In the citing paper
“ApoE4, found in 65–80% of cases of sporadic and familial Alzheimer's disease, increases the occurrence of AD by ∼12 fold in two ɛ4 allele carriers, compared with those with no ɛ4 allele (Farrer et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Farrer et al., 1997
In the citing paper
“The APOE4 allele is a major genetic risk factor for late-onset AD and was previously shown to accelerate AD progression in humans and in mouse models 6-11 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [43]
In the citing paper
“Separately, clinical studies have reported that women APOE ε4 carriers had a higher risk of Alzheimer’s dementia than men carriers [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“Furthermore, a recent meta-analysis of 58000 participants showed that APOE ε3/ε4 women have the same increased odds of AD dementia as APOE ε3ε4 men have, in contrast to a previous meta-analysis which reported APOE ε4 women to carry a higher risk of Alzheimer’s dementia compared to APOE ε4 men [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“As APOE4 carriers make up 55–75% of AD cases17–20”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [18]
In the citing paper
“The initial intriguing observation that the APOEε4 allele increases AD risk differentially across races and ethnicities, with the greatest increase in risk seen in East Asian people, followed by white, then Black, then Hispanic people6, has now been confirmed by a larger meta-analysis using not only self-reported race and ethnicity but also global genetic ancestry to ascertain the biological basis”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“Rather, age and sex moderate the effects of the APOE genotype on AD risk so that the risk associated with the APOEε3/ε4 genotype is highest in women of ages 60–70 years (or 70–80 years according to ref. 6) but decreases in older women and equalizes to that of non-Hispanic White, Black and Hispanic men of the same age10.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“The APOE polymorphism is the most studied, successfully replicated, and well-established risk factor for AD where APOE*2 is the protective allele and APOE*4 is the risk allele as compared to APOE*3 [7–10].”
From Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk (2023) · cites this paper as [8]
In the citing paper
“The original association study implicating L28P with LOAD risk was carried out in a relatively small sample size.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“due to the complete linkage disequilibrium of L28P with APOE*4 (C112R)”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“it was associated with an elevated risk for AD [9]”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“In 1999, two groups independently identified a novel and rare missense mutation in the APOE gene [9, 10] in which the leucine residue is replaced by proline at codon 28 (L28P; rs769452).”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“with the East Asian population having a higher risk of AD associated with the APOE ε4 allele”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“while the effect of APOE ε4 is weaker in African American and Hispanic populations”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“The AD risk associated with common APOE alleles ε4 1 and ε2 2 is well established in European-ancestry individuals but varies considerably across other ancestries (Table 1). 3”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [3]
In the citing paper
“Among the AD susceptibility genes/loci identified to date, APOE remains the most significant genetic risk factor across populations.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [8]
In the citing paper
“Although there is only about 20% of the population carrying the APOE ε4, this isoform is vastly enriched in AD patients with over 60% of symptomatic AD patients carrying at least one APOE ε4 allele”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Farrer et al 1997
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset Alzheimer’s disease (AD).”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [5]
In the citing paper
“The genetic polymorphism of human apolipoprotein E (ApoE) has been shown to confer differential susceptibility to late-onset AD, which accounts for the majority of the AD cases (Farrer et al., 1997).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Farrer et al., 1997
In the citing paper
“occurs in approximately two-thirds of all cases [1–3]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease (AD)”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“In contrast, APOE3 is defined as risk-neutral while APOE2 represents the strongest genetic protective factor (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Farrer et al., 1997
In the citing paper
“Since then, numerous studies have confirmed that possession of the ε4 allele is the strongest genetic risk factor for both AD and CAA, or a combination of both disorders (Bertram et al., 2007; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“However, in certain ethnic groups, the apoE ε4 allele seems to have either a weaker effect or no clear effect on AD (Farrer et al., 1997; Kalaria et al., 2008; Mayeux, 2003; Tang et al., 1998).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“Finally, it is important to note that the ε2 allele of apoE is associated with a lower risk for AD (Corder et al., 1994; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“APOE genotypes were in Hardy-Weinberg equilibrium in both cases and controls; their frequencies (Table 4) were similar to previous reports for the relevant age groups (44;47;48).”
From Association of ALS with head injury, cigarette smoking and APOE genotypes (2010) · cites this paper as [47]
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic Alzheimer's Disease (AD).”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“An APOE ε4/ε4 individual of European ancestry has a sixteen-fold increase in AD risk and eighteen year earlier age at AD onset compared to a European ancestry individual carrying two copies of the more prevalent APOE ε3 allele 4 .”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“The global frequency of the human ε4 allele is 13.7%, and the frequency of ε4 carriers is increased to 40% in AD patients [452, 453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“Clinical incidence and average age of AD onset was found to be 91% at 68 years of age in ε4 homozygous carriers, 47% at 76 years of age in ε4 heterozygous carriers, and 20% at 84 years of age in non-ε4 individuals [453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“ApoE4 is present in roughly 20–25% of the human population, and apoE4 carriers account for 60–75% of AD cases in most clinical studies [11], highlighting the importance of apoE4 in AD pathogenesis.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“ApoE4 increases the risk and decreases the age of onset of AD in a gene dose dependent manner [4–11].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“the effect of APOEε4 has been reported to differ across ethnicities [58–61]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“the association between ε4 and disease is reported to be weaker among African-American and Hispanic individuals [58, 61, 62] and nonexistent among Nigerian individuals [63].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“APOEε2/APOEε4 individuals are still at increased risk for AD, suggesting the APOEε4 isoform exhibits some dominant effect over the APOEε2 isoform [58].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“Several studies have demonstrated APOE genotype has an exacerbated effect on disease risk in females [58]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Items 301–400 of 1,178
Apolipoprotein E and cognitive performance
Raber, J., Wong, D., Yu, G.-Q., Buttini, M., Mahley, R. W., Pitas, R. E., & Mucke, L. (2000) · Nature · doi:10.1038/35006165 · Cited by 237
APOE Genotype Effects on Alzheimer's Disease Onset and Epidemiology
Ashford, J. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:157 · Cited by 239
“Those individuals with the ε3/3 genotype constitute 60% of the population but only 35% of the cases (Table 2; Saunders et al., 1993; Jarvik et al., 1995; Roses, 1995; Myers et al., 1996; Farrer et al., 1997).”
BackgroundMaternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism
Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., De Santi, S., & de Leon, M. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705036104 · Cited by 237
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt187 · Cited by 249
Mosconi, L., Rahman, A., Diaz, I., Wu, X. L., Scheyer, O., Hristov, H., Vallabhajosula, S., Isaacson, R., de Leon, M. J., & Brinton, R. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207885 · Cited by 259
Genetics of Alzheimer's Disease: A Centennial Review
Ertekin‐Taner, N. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.009 · Cited by 243
Bondi, M. W., Salmon, D. P., Galasko, D., Thomas, R. G., & Thal, L. J. (1999) · Psychology and Aging · doi:10.1037//0882-7974.14.2.295 · Cited by 235
Age-related decline in brain resources magnifies genetic effects on cognitive functioning
Lindenberger, U. (2008) · Frontiers in Neuroscience · doi:10.3389/neuro.01.039.2008 · Cited by 233
The Role of Sex and Sex Hormones in Neurodegenerative Diseases
Vegeto, E., Villa, A. M., Torre, S. D., Crippa, V., Rusmini, P., Cristofani, R., Galbiati, M., Maggi, A. C., & Poletti, A. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz005 · Cited by 240
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetic Consortium (ADGC), Li, Z., Kapoor, M., Harari, O., Del-Aguila, J. L., Black, K., Carrell, D., Cai, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1685-y · Cited by 231
Self-citationNeuroprotective Natural Products for Alzheimer’s Disease
Chen, X., Drew, J., Berney, W., & Lei, W. (2021) · Cells · doi:10.3390/cells10061309 · Cited by 236
Tran, T. T. T., Corsini, S., Kellingray, L., Hegarty, C., Le Gall, G., Narbad, A., Müller, M., Tejera, N., O'Toole, P. W., Minihane, A.-M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900071r · Cited by 233
Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231
Beta‐amyloid deposition and the aging brain
Rodrigue, K. M., Kennedy, K. M., & Park, D. C. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9118-x · Cited by 230
“…Deposition Risk There is a large literature on the risk conveyed by carrying the APOE-ε4 allele for age-related decline in cognitive function in both normal adults and AD patients and this is the best characterized genetic polymorphism associated with AD (Corder et al. 1993; Farrer et al. 1997).”
BackgroundLoera-Valencia, R., Goikolea, J., Parrado-Fernandez, C., Merino-Serrais, P., & Maioli, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.003 · Cited by 214
The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity
Abondio, P., Sazzini, M., Garagnani, P., Boattini, A., Monti, D., Franceschi, C., Luiselli, D., & Giuliani, C. (2019) · Genes · doi:10.3390/genes10030222 · Cited by 240
Family-Based Association between Alzheimer's Disease and Variants inUBQLN1
Bertram, L., Hiltunen, M. O., Parkinson, M., Ingelsson, M., Lange, C., Ramasamy, K., Mullin, K., Menon, R., Sampson, A. J., Hsiao, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042765 · Cited by 229
Cognitive leisure activities and their role in preventing dementia: a systematic review
Stern, C., & Munn, Z. (2010) · International Journal of Evidence-Based Healthcare · doi:10.1111/j.1744-1609.2010.00150.x · Cited by 228
Demonstrating the case that AD is a vascular disease: epidemiologic evidence
Launer, L. J. (2002) · Ageing Research Reviews · doi:10.1016/s0047-6374(01)00364-5 · Cited by 231
Wijsman, E. M., Pankratz, N., Choi, Y., Rothstein, J. H., Faber, K. M., Cheng, R., Lee, J. H., Bird, T. D., Bennett, D. A., Diaz-Arrastia, R. R., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001308 · Cited by 229
Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways
Zhao, N., Ren, Y., Yamazaki, Y., Qiao, W., Li, F., Felton, L. M., Mahmoudiandehkordi, S., Kueider-Paisley, A., Sonoustoun, B., Arnold, M., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.034 · Cited by 225
“The APOE4 gene allele is the strongest genetic risk factor for lateonset AD, whereas APOE2 is protective compared to the common APOE3 allele (Bu, 2009; Farrer et al., 1997).”
BackgroundDementia and Race: Are There Differences Between African Americans and Caucasians?
Miles, T. P., Froehlich, T. E., Bogardus, S. T., & Inouye, S. K. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49096.x · Cited by 225
Genetics of Alzheimer’s disease: where we are, and where we are going
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.024 · Cited by 215
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
“A meta-analysis of 40 studies allowed the formulation of odds ratios (OR) for AD within different ethnic backgrounds (Farrer et al. 1997).”
BackgroundInfluentialWalker, L., McAleese, K. E., Thomas, A. J., Johnson, M. A., Martin-Ruiz, C. M., Parker, C., Colloby, S. J., Jellinger, K. A., & Attems, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1406-3 · Cited by 224
“Up to 65 % of all pathologically confirmed AD cases carry at least one ε4 allele and 12–15 % are homozygous for ε4 compared to 1–3 % of healthy individuals [10, 27].”
McDonald, B. C., Conroy, S. K., Smith, D. J., West, J. D., & Saykin, A. J. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.05.007 · Cited by 223
“By comparison, in a meta-analysis Farrer et al. (1997) found that 25.7% of a group of 6262 Caucasian healthy older adults were APOE e4 positive, in contrast to patients with Alz heimer’s disease, of whom 58.5% were APOE e4 positive.”
InfluentialThakkinstian, A., Han, P., McEvoy, M., Smith, W. T., Hoh, J. J., Magnússon, K. P., Zhang, K., & Attia, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl220 · Cited by 227
“Previous meta-analysis of ApoE and Alzheimer’s disease in European ancestry subjects showed an OR for the combined E4E4 and E3E4 versus E3E3 genotypes of 4.05, and the proportion of E4E4 and E3E4 in control population was 23.1% ( 48 ), giving an estimated PAR of 41.3%.”
BackgroundInfluentialSteenland, K., Goldstein, F. C., Levey, A. I., & Wharton, W. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150778 · Cited by 226
ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response
Wang, C., Zhang, M., Garcia, G., Tian, E., Cui, Q., Chen, X., Sun, G., Wang, J., Arumugaswami, V., & Shi, Y. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.018 · Cited by 222
Meat‐Adaptive Genes and the Evolution of Slower Aging in Humans
Finch, C. E., & Stanford, C. B. (2004) · The Quarterly Review of Biology · doi:10.1086/381662 · Cited by 216
Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
Amyloid burden and neural function in people at risk for Alzheimer's Disease
Johnson, S. C., Christian, B. T., Okonkwo, O. C., Oh, J. M., Harding, S., Xu, G., Hillmer, A. T., Wooten, D. W., Murali, D., Barnhart, T. E., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.028 · Cited by 218
“It is known that the effect of APOE4 on risk for AD is greater in women (Farrer et al., 1997).”
BackgroundThe Effect of Borderline Diabetes on the Risk of Dementia and Alzheimer’s Disease
Xu, W., Qiu, C., Winblad, B. G., & Fratiglioni, L. (2006) · Diabetes · doi:10.2337/db06-0879 · Cited by 221
The Worldwide Challenge of the Dementias: A Role for B Vitamins and Homocysteine?
Smith, A. D. (2008) · Food and Nutrition Bulletin · doi:10.1177/15648265080292s119 · Cited by 221
Statins for the treatment of dementia
McGuinness, B., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 236
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
Arenaza‐Urquijo, E. M., Boyle, R., Casaletto, K., Anstey, K. J., Vila‐Castelar, C., Colverson, A., Palpatzis, E., Eissman, J. M., Kheng Siang Ng, T., Raghavan, S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13844 · Cited by 223
Incidence of Mild Cognitive Impairment: A Systematic Review
Luck, T., Luppa, M., Briel, S., & Riedel-Heller, S. G. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000272424 · Cited by 213
Leisure‐time physical activity from mid‐ to late life, body mass index, and risk of dementia
Tolppanen, A., Solomon, A., Kulmala, J., Kåreholt, I., Ngandu, T., Rusanen, M., Laatikainen, T. K., Soininen, H. S., & Kivipelto, M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.01.008 · Cited by 231
Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 219
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., Asthana, S., & Johnson, S. C. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-1 · Cited by 215
The Eye As a Biomarker for Alzheimer's Disease
Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Wong, V. H. Y., Currier, N. V., Mullen, J., Bui, B. V., & Nguyen, C. T. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00536 · Cited by 221
“Carriers of the apolipoprotein E (APOE) ǫ4 allele (13.7% of the world’s population) face an increased risk of developing the disease (Farrer et al., 1997), depending on whether they have one or two copies of the ǫ4 allele.”
BackgroundInfluentialSubramaniapillai, S., Almey, A., Rajah, M. N., & Einstein, G. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100879 · Cited by 215
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
Genetics of Alzheimer’s Disease
Chouraki, V. A., & Seshadri, S. S. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 220
Molecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Broeckhoven, C. V. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 213
APOE ε4 is associated with obstructive sleep apnea/hypopnea
Gottlieb, D. J., DeStefano, A. L., Foley, D., Mignot, E. J.-M., Redline, S. S., Givelber, R. J., & Young, T. B. (2004) · Neurology · doi:10.1212/01.wnl.0000134671.99649.32 · Cited by 207
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Hurtig, H. I., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Rhodes, S. L., Factor, S. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1455 · Cited by 203
The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms☆
Finch, C. E., & Sapolsky, R. M. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00053-6 · Cited by 208
Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations
Rajabli, F., Feliciano, B. E., Celis, K., Hamilton-Nelson, K. L., Whitehead, P. L., Adams, L. D., Bussies, P. L., Manrique, C. P., Rodriguez, A., Rodriguez, V., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007791 · Cited by 206
Self-citationGenome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a397 · Cited by 206
Gender differences in dementia risk factors
Azad, N. A., Bugami, M. A., & Loy-English, I. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80026-x · Cited by 211
Midlife sleep characteristics associated with late life cognitive function
Virta, J. J., Heikkilä, K., Perola, M., Koskenvuo, M., Räihä, I., Rinne, J. O., & Kaprio, J. (2013) · Sleep · doi:10.5665/sleep.3052 · Cited by 200
Relationship between case-control studies and the transmission/disequilibrium test
Mitchell, L. E. (2000) · Genetic Epidemiology · doi:10.1002/1098-2272(200010)19:3 · Cited by 19
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
“Carriers of the 4-allele have an increased risk of developing AD [236] as well as a decreased age of AD onset [237] compared to non- 4 carriers.”
BackgroundIL-33 and IL-33 Receptors in Host Defense and Diseases
Oboki, K., Ohno, T., Kajiwara, N., Saito, H., & Nakae, S. (2010) · Allergology International · doi:10.2332/allergolint.10-rai-0186 · Cited by 210
APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints
Yin, Z., Rosenzweig, N., Kleemann, K. L., Zhang, X., Brandão, W., Margeta, M. A., Schroeder, C., Sivanathan, K. N., Silveira, S., Gauthier, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01627-6 · Cited by 202
Lehmann, D. J., Cortina-Borja, M., Warden, D. R., Smith, A. D., Sleegers, K., Prince, J. A., van Duijn, C. M., & Kehoe, P. G. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi202 · Cited by 199
Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease
Chapuis, J., Hot, D., Hansmannel, F., Kerdraon, O., Ferreira, S., Hubans, C., Maurage, C. A., Huot, L., Bensemain, F., Laumet, G., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.10 · Cited by 201
Impact of APOE in mild cognitive impairment
Farlow, M. R., He, Y., Tekin, S., Xu, J., Lane, R. M., & Charles, H. C. (2004) · Neurology · doi:10.1212/01.wnl.0000144279.21502.b7 · Cited by 200
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Psychosis in Alzheimer’s Disease
Murray, P. S., Kumar, S., DeMichele‐Sweet, M. A. A., & Sweet, R. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.020 · Cited by 203
Transethnic genome‐wide scan identifies novel Alzheimer's disease loci
Jun, G. R., Chung, J., Mez, J., Barber, R., Beecham, G. W., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Carrasquillo, M. M., Crane, P. K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.012 · Cited by 197
Apostolova, L. G. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000307 · Cited by 277
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
“The proportion of APOE2 in long-lived elderly European and American populations is almost twice that of the general life-span population, while the frequency of APOE2 allele in AD patients is extremely low [53].”
BackgroundIdentification of Novel Genes in Late-Onset Alzheimer's Disease
Pericak‐Vance, M. A., Grubber, J. M., Bailey, L., Hedges, D. J., West, S. G., Santoro, L., Kemmerer, B., Hall, J. L., Saunders, A. M., Roses, A. D., et al. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00196-0 · Cited by 196
Prevalence of Alzheimer’s disease in very elderly people: A prospective neuropathological study
Polvikoski, T., Sulkava, R., Myllykangas, L., Notkola, I.-L., Niinistö, L., Verkkoniemi, A., Kainulainen, K., Kontula, K., Pérez–Tur, J., Hardy, J., et al. (2001) · Neurology · doi:10.1212/wnl.56.12.1690 · Cited by 197
Miyashita, A., Koike, A., Jun, G., Wang, L.-S., Takahashi, S., Matsubara, E., Kawarabayashi, T., Shoji, M., Tomita, N., Arai, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058618 · Cited by 196
Self-citationRelation between smoking and risk of dementia and Alzheimer disease
Reitz, C., den Heijer, T., van Duijn, C. M., Albert Hofman, D., & Breteler, M. M. B. (2007) · Neurology · doi:10.1212/01.wnl.0000271395.29695.9a · Cited by 200
Kukull, W. A., & Ganguli, M. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70233-4 · Cited by 194
Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 273
Alternative splicing in neurodegenerative disease and the promise of RNA therapies
Nikom, D., & Zheng, S. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00717-6 · Cited by 201
The Pathogenesis of Alzheimers Disease—Is It a Lifelong “Calciumopathy”?
Stutzmann, G. E. (2007) · The Neuroscientist · doi:10.1177/1073858407299730 · Cited by 199
Emrani, S., Arain, H. A., DeMarshall, C. A., & Nuriel, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 207
Association of an interleukin 1α polymorphism with Alzheimer’s disease
Du, Y., Dodel, R. C., Eastwood, B. J., Bales, K. R., Gao, F., Lohmüller, F., Müller, U., Kurz, A., Zimmer, R., Evans, R. M., et al. (2000) · Neurology · doi:10.1212/wnl.55.4.480 · Cited by 195
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
“One APOE-e4 allele increases the risk of AD by three times (heterozygotes) and two APOE-e4 alleles increase the risk of AD by 15 times (homozygotes) (Farrer et al. 1997).”
Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment
Piehl, N., van Olst, L., Ramakrishnan, A., Teregulova, V., Simonton, B., Zhang, Z., Tapp, E., Channappa, D., Oh, H. S., Losada, P. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.019 · Cited by 208
Huebbe, P., & Rimbach, G. H. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.06.002 · Cited by 202
Bos, D., Wolters, F. J., Darweesh, S. K. L., Vernooij, M. W., de Wolf, F., Ikram, M. A., & Albert Hofman, D. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.007 · Cited by 202
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“…across races and ethnicities, with the greatest increase in risk seen in East Asian people, followed by white, then Black, then Hispanic people 6 , has now been confirmed by a larger meta-analysis using not only self-reported race and ethnicity but also global genetic ancestry to ascertain…”
Jorm, A. F., Butterworth, P., Anstey, K. J., Christensen, H. M., Easteal, S., Maller, J. J., Mather, K. A., Turakulov, R. I., WEN, W., & Sachdev, P. S. (2004) · Psychological Medicine · doi:10.1017/s0033291704003162 · Cited by 201
Ji, Y., Gong, Y., Gan, W., Beach, T., Holtzman, D. M., & Wisniewski, T. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.007 · Cited by 189
“The odds ratio for apoE genotypes 2/ 4, 3/ 4, 4/ 4 are 2.6, 3.3 and 14.9 respectively ( Farrer et al., 1997 ).”
BackgroundInfluentialCell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
“Carriers of the APOE ε4 allele, the strongest genetic risk factor for late-onset AD 10,14,15 , account for approximately 24% of the healthy population 16 (Fig.”
Holthoff, V. A., Beuthien-Baumann, B., Kalbe, E., Lüdecke, S., Lenz, O., Zündorf, G., Spirling, S., Schierz, K., Winiecki, P., Sorbi, S., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.035 · Cited by 190
Rahman, A., Jackson, H. C., Hristov, H., Isaacson, R., Saif, N., Shetty, T., Etingin, O. R., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 204
“It has long been known that, after advanced age, female sex is the major risk factor for AD (Farrer et al., 1997).”
BackgroundInfluentialThe neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
Beffert, U. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00008-3 · Cited by 190
Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits
Raber, J., Bongers, G., LeFevour, A., Buttini, M., & Mucke, L. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-12-05204.2002 · Cited by 187
Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., Pirraglia, E., Tsui, W., De Santi, S., & de Leon, M. J. (2009) · Neurology · doi:10.1212/01.wnl.0000333247.51383.43 · Cited by 188
Zalocusky, K. A., Najm, R., Taubes, A. L., Hao, Y., Yoon, S. Y., Koutsodendris, N., Nelson, M. R., Rao, A., Bennett, D. A., Bant, J., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00851-3 · Cited by 189
Interpreting Meta-Analyses of Genome-Wide Association Studies
Han, B., & Eskin, E. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002555 · Cited by 177
“It is reported that different populations can cause such phenomenon [19,20,30,31].”
Mandelblatt, J. S., Small, B. J., Luta, G., Hurria, A., Jim, H., McDonald, B. C., Graham, D. M. A., Zhou, X., Clapp, J. D., Zhai, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00140 · Cited by 188
Gillespie, A. K., Jones, E. A., Lin, Y.-H., Karlsson, M. P., Kay, K., Yoon, S. Y., Tong, L. M., Nova, P., Carr, J. S., Frank, L. M., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.009 · Cited by 187
“Present in 65%–80%of AD cases, apoE4 increases the incidence of AD and lowers the age of onset in a gene dose-dependent manner (Farrer et al., 1997) compared to the most common isoform, apoE3.”
BackgroundSex and gender differences in the causes of dementia: A narrative review
Rocca, W. A., Mielke, M. M., Vemuri, P., & Miller, V. M. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.008 · Cited by 186
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
“APOE has its greatest influence on the risk for AD between about 65 and 70 years of age and declines substantially by age 85 due to survival effects [11].”
BackgroundAlzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Battista, A. M. D., Heinsinger, N. M., & Rebeck, G. W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160401115127 · Cited by 189
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 194
Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease
Coughlan, G., Coutrot, A., Khondoker, M. R., Minihane, A. M., Spiers, H. J., & Hornberger, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901600116 · Cited by 191
Metadata
- Authors
- Farrer, L. A.
- Corresponding author
- Farrer, Lindsay A.
- ORCID
- Farrer, Lindsay A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-10-22
- Volume
- 278
- Issue
- 16
- Pages
- 1349
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W7028228764
- Cited by
- 124
- References
- 0
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 6 · 2023: 12 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, genetic risk, age of onset, sex differences, ethnic differences, African Americans, Hispanic population, Japanese population, genetic heterogeneity, dementia risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
